China’s Best Shot: GSK, Novartis Gear Up For Vaccine Prime Time
This article was originally published in PharmAsia News
With its large population, one-child policy and increasing emphasis on preventative care, China is poised for a vaccine boom. The catalyst for growth may come from the expected modernization of the country’s massive national immunization program.
You may also be interested in...
Vaccines Shakeup Continues In China: NT Pharma Backs Away From GSK
SHANGHAI - China's largest vaccine distributor China NT Pharma Group announced Aug. 17 it will not renew its master distribution contract with its largest customer GlaxoSmithKline PLC, in part, it appears, due to burdens created by the new China Pharmacopeia that was issued at the end of 2010
With Limits Created By China's New Pharmacopoeia, What's Next For Vaccine Manufacturers?
SHANGHAI - China is expected to be the world's largest vaccine market by 2020, and every vaccine maker is trying to increase their presence to gain market share. However, the new Chinese Pharmacopoeia might put these efforts to an end and almost all vaccines from multinational companies may have to withdraw from China if they fail to comply with new standards
GSK Buys Out Neptunus Stake in Chinese Vaccines JV; Are New Pharmacopoeia Standards At Play?
In an effort to increase its footprint in the Chinese vaccine market, GlaxoSmithKline PLC will acquire the remaining 51% equity stake in its joint venture with China's Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. for $39 million in cash, the companies announced June 14